Associations of MDM2 rs2279744 and TP53 rs1042522 polymorphisms with cervical cancer risk: A meta-analysis and systematic review

Abstract

BackgroundAlthough the association between MDM2 rs2279744 and TP53 rs1042522 polymorphisms and cervical cancer has been reported, the results of its correlation were contradictory. Thus, we conducted a meta-analysis to precisely verify the relationships between MDM2 rs2279744 and TP53 rs1042522 polymorphisms and cervical cancer.MethodsWe thoroughly searched the PubMed, Web of Science, Embase, and Scopus databases for all potential articles from inception to June 2022 and used R Version 4.1.2 and STATA software 12.0 for the meta-analysis. The odds ratios (ORs), 95% confidence intervals (CIs) and 95% prediction intervals (PIs) were calculated to evaluate the associations. Subgroup analyses stratified by ethnicity, source of control, quality score and adjustment were further conducted to assess the relationship between MDM2 rs2279744 and TP53 rs1042522 polymorphisms and cervical cancer.ResultsA total of 30 case-control studies involving 5025 cases and 6680 controls were included. All the included studies were population-based or hospital-based studies. The overall analysis showed that MDM2 rs2279744 polymorphism was closely related to an increased risk of cervical cancer in the recessive model (GG vs GT + TT: OR = 1.602, 95% CI: 1.077-2.383, P = 0.020) and homozygote model (GG vs TT: OR = 1.469, 95% CI: 1.031-2.095, P = 0.033, 95% PI: 0.516-4.184). A significant correlation between TP53 rs1042522 polymorphism and cervical cancer was observed in two models (CC + CG vs GG: OR = 1.759, 95% CI: 1.192-2.596, P = 0.004, 95% PI: 0.474-6.533; GG vs CC: OR = 2.442, 95% CI: 1.433-4.162, P = 0.001, 95% PI: 0.456-13.071).ConclusionsThis meta-analysis revealed that MDM2 SNP309T>G and TP53 rs1042522 C>G polymorphisms were associated with the increased risk of cervical cancer.

The association of TP53 (Arg72Pro) rs1042522 C>G polymorphism and colorectal cancer susceptibility in Duhok individuals

“…In a meta-analysis and systematic review study done by Yu et al, a total of 30 case-control studies involving 5025 cases and 6680 controls were included. A significant correlation between TP53 rs1042522 polymorphism and cervical cancer was observed in two models (CC; CG vs. GG; GG vs CC) (Yu et al, 2022). Further study is needed to identify an association between the TP53 rs1042522 polymorphism and the risk of CRC.…”

Interactive Association of XRCC1, XRCC2, XRCC3, and TP53 Gene Polymorphisms With Gastrointestinal Cancer Risk: Insights From a Hospital-Based Case-Control Study

“…Particularly, the Arg194Trp and Arg399Gln variants of XRCC1, the Arg188His variant of XRCC2, and the Thr241Met variant of XRCC3 have been studied for their associations with various types of cancer [5][6][7]. Similarly, the SNPs Arg72Pro and Arg249Ser in TP53 have been frequently investigated for their correlation with cancer risk [8][9][10]. However, there is a dearth of literature exploring the combined effects of genetic polymorphisms in the XRCC1, XRCC2, XRCC3, and TP53 genes for their involvement in cancer risk.…”

TP53 (rs1042522, rs28934571) and TP21 (rs1801270, rs1059234) Polymorphisms and Risk of Breast Cancer among Rural Women of Maharashtra: Findings from a Hospital Based Case- Control Study

“…substitution of arginine to proline, and codon 249 of exon 7 i.e. transition of arginine to serine have been distinctively explored in different populations in relation with carcinogenesis (Zang et al 2018, Ratre et al 2019, Yu et al 2022. The rs1042522, SNP of p53 at codon 72 with a substitution of arginine to proline and rs1801270 SNP of p21 at codon 31 with serine to arginine substitute have been widely studied in diverse group of population for their association with carcinogenesis (Huang et al, 2019;Yu et al 2022), but others reported conflicting results with no association with cancer development (Song et al, 2017;Lin et al, 2018;Nicholas et al, 2019).…”

“…transition of arginine to serine have been distinctively explored in different populations in relation with carcinogenesis (Zang et al 2018, Ratre et al 2019, Yu et al 2022. The rs1042522, SNP of p53 at codon 72 with a substitution of arginine to proline and rs1801270 SNP of p21 at codon 31 with serine to arginine substitute have been widely studied in diverse group of population for their association with carcinogenesis (Huang et al, 2019;Yu et al 2022), but others reported conflicting results with no association with cancer development (Song et al, 2017;Lin et al, 2018;Nicholas et al, 2019). Similar type of epidemiological studies reported from India for those SNPs and their association with cancer development (Lakshmi et al, 2012;Saikia et al, 2014;Khan et al, 2020) whereas other objected for their association with carcinogenesis in different ethnic population (Pillai and Nasir 2016;Bansal et al, 2016).…”

“…To date, several literature information on case-control and other epidemiological studies have identified the association of the p53 and p21 SNPs with susceptibility to cervical ( Datkhile et al, 2019;Ratre et al, 2019;Yu et al, 2022), ovarian (Alqumber et al, 2014), lung (Matikodu et al, 2003), head and neck (Bau et al, 2007) bladder (Zang et al, 2018) and gastric (Song et al, 2011) cancer risk, while others pointed out contrast observations where these SNPs did not show any association of either p53 or p21 polymorphism with development of oral (Lin et al, 2018) ovarian (Alqumber et al, 2014), colorectal (Asadi et al, 2017), lung (Nicholas et al, 2019), prostate (Sivonova et al, 2015;Song et al, 2017) and cervical cancer risk (Martinez-Nava et al, 2016). Thus, it is not clear from the earlier evidences that the polymorphisms in tumor suppressor molecules may play a role in genetic susceptibility of variety of cancers and the findings appeared conflicting.…”